Harmony Biosciences Reconnect Study Update
- Fragile X Society
- Sep 25
- 1 min read
Harmony Biosciences has shared the results of their Phase 3 trial RECONNECT Study. Unfortunately, the study did not meet its primary goal.
We know this will be disappointing news for many families and researchers who were hopeful about this treatment. However, every clinical trial adds valuable knowledge that will help guide future research into Fragile X and bring us closer to effective therapies.
As always, we will continue to encourage and support further research and will keep you updated as more is learned.
For more information, please refer to the documents below, that provides the update and the statement issued by Harmony.